neuraxis.com (NRXS) - Kewajiban jangka dawa marang modal

NeurAxis, Inc. - logo grafis emiten NRXS

The NeurAxis, Inc. (NRXS) business is protected by the humanitarian status of medicine, which minimizes external political risks. The dynamics of the long-term debt-to-equity ratio demonstrate the current vector of financial autonomy, where 0.02 expresses the latest level of the metric. The recurring sales model for consumables ensures a sustainable margin, while the defensive nature of neurostimulation guarantees stable demand regardless of economic cycles.

NeurAxis Inc. (NRXS): Utang jangka dawa marang ekuitas saka 21.02.2024 nganti 30.10.2026
Produk asli NeurAxis Inc.

This ratio is calculated as long-term liabilities divided by equity, reflecting the impact of debt financing on total asset value. The metric measures the company's degree of dependence on creditors with maturities exceeding one year. For NeurAxis, Inc. (NRXS), such a capital structure is critical when outsourcing production and clinical trials. Analyzing long-term credit leverage allows for an assessment of the business model's resilience to rising interest rates.

Perusahaan pesaing

Rasio utang jangka dawa marang modal BIIB (Biogen Inc)|Utang jangka dawa marang modal NBIX|RGC - Kewajiban jangka dawa marang modal|Axsome Therapeutics - Rasio utang jangka dawa marang ekuitas|Utang jangka dawa marang modal acadia-pharm.com ACAD|XENE - Utang jangka dawa marang ekuitas|Koefisien utang jangka dawa marang modal VKTX (Viking Therapeutics Inc)|Supernus Pharma (SUPN) - Utang jangka dawa marang ekuitas|Kewajiban jangka dawa marang modal Catalyst Corp (CPRX)|Utang jangka dawa marang ekuitas Denali Therapeutics|Rasio utang jangka dawa marang modal HRMY (harmonybiosciences.com)|Utang jangka dawa marang modal BHVN|AMLX - Kewajiban jangka dawa marang modal|Trevi Pharma - Rasio utang jangka dawa marang ekuitas|Utang jangka dawa marang modal Praxis Corp PRAX|AVXL - Utang jangka dawa marang ekuitas|Koefisien utang jangka dawa marang modal CBLL (ceribell.com)|PRTA: Utang jangka dawa marang modal|Alector (ALEC) - Utang jangka dawa marang modal|Rasio utang jangka dawa marang ekuitas ANNX|Rasio utang jangka dawa marang modal OMER (Omeros Corp.)|Utang jangka dawa marang modal NGNE|Rasio tanggungan utang jangka dawa marang modal acimmune.com|Utang jangka dawa marang ekuitas Voyager Therapeutics, Inc. VYGR|Rasio tanggungan utang jangka dawa marang modal Neumora (NMRA)|SCLX: Rasio utang jangka dawa marang ekuitas|Koefisien utang jangka dawa marang modal TVGN (Tevogen Bio Inc.)|ACOG: Utang jangka dawa marang modal|CGTX - Rasio tanggungan utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Inhibikase Therapeutics, Inc.|Rasio utang jangka dawa marang modal SAVA (Cassava Sciences Inc)|Utang jangka dawa marang modal ASRT|Rasio utang jangka dawa marang ekuitas coyatherapeutics.com COYA|Vistagen - Rasio utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka dawa marang modal Ovid Therapeutics Inc (OVID)|ABOS - Utang jangka dawa marang ekuitas|CRVO (CervoMed, Inc.) - Rasio utang jangka dawa marang modal|alteritytherapeutics.com (ATHE) - Utang jangka dawa marang ekuitas|Clene - Koefisien utang jangka dawa marang modal|Rasio utang jangka dawa marang ekuitas PEPG|Rasio utang jangka dawa marang modal JUNS (jupiterneurosciences.com)|Utang jangka dawa marang ekuitas Relmada Therapeutics, Inc. (RLMD)|Rasio tanggungan utang jangka dawa marang modal Annovis Bio Inc|Utang jangka dawa marang ekuitas Grace Therapeutics GRCE|AIFF: Rasio utang jangka dawa marang modal|ANEW Medical, Inc. - Utang jangka dawa marang modal|Kewajiban jangka dawa marang modal NeuroSense Therapeutics|RVPH (Reviva Pharmaceuticals Holdings, Inc.) - Rasio utang jangka dawa marang ekuitas|MetaVia (MTVA) - Utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Helius Medical Technologies, Inc.|PASG: Koefisien utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Neuphoria Therapeutics Inc. (NEUP)|NERV - Kewajiban jangka dawa marang modal|Utang jangka dawa marang ekuitas Athira Pharma ATHA|ADXN: Rasio utang jangka dawa marang modal|Alzamend - Utang jangka dawa marang modal|Kewajiban jangka dawa marang modal Cyclerion Therapeutics|PTIX (protagenic.com) - Rasio utang jangka dawa marang ekuitas|Pasithea Therapeutics Corp. (KTTA) - Utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Cortigent Inc|ATXI: Koefisien utang jangka dawa marang modal|Utang jangka dawa marang modal BCLI|Utang jangka dawa marang modal Cara Therapeutics Inc (CARA)|Chromocell Therapeutics - Rasio utang jangka dawa marang ekuitas|ELYM: Rasio utang jangka dawa marang modal|Intra-Cellular - Utang jangka dawa marang modal|Rasio tanggungan utang jangka dawa marang modal Longboard Pharmaceuticals Inc LBPH|Marinus (MRNS) - Utang jangka dawa marang ekuitas|NKGN - Rasio tanggungan utang jangka dawa marang modal|Rasio utang jangka dawa marang ekuitas NRBO|SAGE: Koefisien utang jangka dawa marang modal|Utang jangka dawa marang modal SNPX|Rasio tanggungan utang jangka dawa marang modal Trevena Inc.|Utang jangka dawa marang ekuitas Vigil Neuroscience, Inc. VIGL|WENA: Rasio utang jangka dawa marang modal|Cerevel Therapeutics - Utang jangka dawa marang modal